Summary: Hypertension is the second most common cardiovascular risk factor after hypercholesterolemia. It occurs in approximately one-third of all Polish adults and in three-quarters of Poles over the age of 60. In addition to its high prevalence, hypertension is a very strong risk factor responsible for cardiac, vascular, cerebral, renal, and ocular complications. This makes high blood pressure the most important risk factor worldwide leading to death or life with disability. A reduction in systolic blood pressure by 10 mmHg and diastolic blood pressure by 5 mmHg leads to a 46% reduction in the risk of developing heart failure, a 37% reduction in the risk of stroke, a 22% reduction in the risk of ischemic heart disease, and, as a result, a 20% reduction in cardiovascular mortality. According to current guidelines, the gold standard for antihypertensive pharmacotherapy is combination drugs (SPC), which should be used at every stage of treatment, from initiation to intensification. Preparations containing long-acting drugs are preferred, as they are administered once a day, provide 24-hour BP control, and protect the patient from the phenomenon of morning blood pressure rise. These include combinations of perindopril, indapamide, and amlodipine. The available preparations (two- and three-component combinations) are characterized by pharmacokinetics that ensure stable BP control, without episodes of BP increase or episodes of hypotension. They are well tolerated by patients and have a proven effect on improving treatment adherence, improving BP control, and consequently reducing the risk of organ complications and cardiovascular events.